BR100 Increased By (0.02%)
BR30 Decreased By (-0.24%)
KSE100 Increased By (0.04%)
KSE30 Increased By (0.04%)
AGHA 6.70 Increased By ▲ 0.02 (0.3%)
BECO 4.39 Increased By ▲ 0.02 (0.46%)
BML 56.95 Decreased By ▼ -0.37 (-0.65%)
BOP 30.36 Increased By ▲ 0.01 (0.03%)
CNERGY 13.10 Decreased By ▼ -0.02 (-0.15%)
CSIL 5.38 Decreased By ▼ -0.03 (-0.55%)
FCCL 52.76 Decreased By ▼ -0.03 (-0.06%)
FFL 14.68 Decreased By ▼ -0.04 (-0.27%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 6.17 Increased By ▲ 0.08 (1.31%)
KOSM 6.10 Increased By ▲ 0.37 (6.46%)
LOTCHEM 26.52 Increased By ▲ 0.06 (0.23%)
MLCF 93.29 Increased By ▲ 0.13 (0.14%)
NBP 165.00 Increased By ▲ 0.34 (0.21%)
NCPL 55.67 Increased By ▲ 0.01 (0.02%)
NPL 60.88 Decreased By ▼ -0.28 (-0.46%)
OGDC 315.50 Decreased By ▼ -1.23 (-0.39%)
PACE 9.95 Increased By ▲ 0.08 (0.81%)
PAEL 35.55 Decreased By ▼ -0.08 (-0.22%)
PIBTL 14.80 Increased By ▲ 0.12 (0.82%)
PPL 224.40 Decreased By ▼ -2.51 (-1.11%)
PRL 92.70 Decreased By ▼ -0.32 (-0.34%)
PTC 60.35 Increased By ▲ 0.09 (0.15%)
SSGC 23.85 Increased By ▲ 0.04 (0.17%)
TBL 8.76 Increased By ▲ 0.01 (0.11%)
TELE 7.80 No Change ▼ 0.00 (0%)
TPL 22.44 Increased By ▲ 0.09 (0.4%)
TPLP 12.89 Decreased By ▼ -0.08 (-0.62%)
TREET 22.18 Increased By ▲ 0.02 (0.09%)
TRG 56.52 Decreased By ▼ -0.04 (-0.07%)
By

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed for this article.